Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Chief Executive Officer

20 Sep 2011 07:00

FOR IMMEDIATE RELEASE

Appointment of Chief Executive Officer

London, September 20, 2011 -Silence Therapeutics plc (AIM: SLN) ("Silence", the "Group" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, today announces the appointment of Thomas Christ©ly as Chief Executive Officer with immediate effect. He will be based at Silence's facility in Berlin.

Thomas Christ©ly (aged 51) brings more than 20 years experience in corporate and business development and finance. He was instrumental in the merger of Silence Therapeutics AG (formerly Atugen AG) with Silence Therapeutics plc (formerly SR Pharma plc) and admission to the Alternative Investment Market of the London Stock Exchange. His track record includes concluding major collaborations with AstraZeneca, Pfizer, Dainippon Sumitomo, multiple financing transactions as well as M&A, divestments and strategic restructurings. He joined Atugen AG in 2001 as Chief Financial Officer and became Chief Operating Officer in 2002 before being appointed its Chief Executive Officer in 2006. Prior to joining Silence, Thomas was Senior VP and CFO at OXO Chemie AG, a Swiss pharmaceutical company, and founded its subsidiary OXO Chemie Inc. in San Francisco, where he stayed from 1997 until 2000. Mr. Christ©ly was managing partner of the investment firm L¶schen & Partner, Hamburg/Moscow, from 1992 to 1995 and worked in mergers & acquisitions at Enskilda Corporate Finance, London, from 1989 to 1992. After his studies in Hamburg and Geneva, he received degrees in Business Administration (equivalent to MBA) and Law from the University of Hamburg and was admitted as attorney-at-law. Thomas Christ©ly is currently Non-executive Chairman of the Supervisory Board of M¼ller-Spreer AG, Hamburg, and CEO of Silence Therapeutics AG.

Jerry Randall, Chairman of Silence Therapeutics, said: "After a thorough selection process of internal and external candidates, we are delighted to announce the appointment of Thomas as CEO. This successfully completes the reorganisation announced earlier this year in order to streamline Silence's operations. Now that Silence has become a wholly European company it is appropriate to have a Chief Executive based in Europe. Thomas has more than 10 years of experience at Silence as CFO, COO and since 2006 as CEO of Silence Therapeutics AG and was instrumental in Silence's major partnerships with pharmaceutical companies. His experience with the team and the science will ensure continuity as we move forward. We are confident that Thomas has the vision, expertise and experience necessary to move the Company toward the achievement of its corporate and clinical objectives."

Commenting on his appointment, Thomas Christ©ly said: "I am delighted to have been appointed CEO of Silence at this very exciting time for the Company. During my time so far at Silence, the Company has made significant clinical progress and now has an enviable portfolio of clinical and pre-clinical assets. With my long term relationships already established with our partners over many years, I look forward to achieving further commercial success from this outstanding pipeline."

Thomas Christ©ly holds 500,000 shares (0.09% of issued share capital) in Silence. No further disclosures are required under AIM Rule 17.

--Ends--

For further information, please contact:

Silence Therapeutics Singer Capital Markets Thomas Christ©ly - CEO Shaun Dobson/Claes Sp¥ng Max Herrmann - CFO +44 20 32057500 +44 20 7491 6520 shaun.dobson@singercm.com m.herrmann@silence-therapeutics.com claes.spang@singercm.com Vida Communication (US) M:Communications (Europe) Tim Brons (media)/Stephanie Diaz Peter Laing / Emma Thompson (investors) +44 20 7920 2345 / +44 20 7920 2342 +1 (415) 675-7400 healthcare@mcomgroup.com tbrons@vidacommunication.com sdiaz@vidacommunication.com Notes for editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry. The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEXâ„¢ and DACC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endothelium with a long duration of target mRNA and protein knock-down. Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEXâ„¢. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as repeated, intravenous administration. Encouraging interim data were presented at the American Society of Clinical Oncology Annual Meeting in June 2011. The study is expected to be completed in the second half of 2011.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of additional partnerships. Silence Therapeutics has operations in both Berlin and London.

# # #

XLON
Date   Source Headline
30th Mar 20167:00 amRNSHolding(s) in Company
22nd Mar 20167:00 amRNSNotice of Results
18th Jan 20167:00 amRNSBoard changes
12th Nov 20157:00 amRNSBoard appointment
30th Oct 20152:32 pmRNSLicensee's drug to commence Ph 2/Ph 3 trials
29th Sep 20157:00 amRNSInterim Results
22nd Sep 20157:19 amRNSBoard Change and Notice of Results
30th Jul 20157:01 amRNSInterim Board Change
1st Jun 201511:42 amRNSResult of AGM
1st Jun 20157:00 amRNSAGM statement and clinical trial interim analysis
14th May 20159:55 amRNSReplacement: Holding(s) in Company
14th May 20157:00 amRNSClinical trial update
12th May 201510:19 amRNSHolding(s) in Company
11th May 20155:31 pmRNSHolding(s) in Company
11th May 20153:07 pmRNSHolding(s) in Company
11th May 20153:07 pmRNSHolding(s) in Company
11th May 201511:29 amRNSHolding(s) in Company
11th May 201510:50 amRNSHolding(s) in Company
11th May 201510:06 amRNSNotice of AGM
8th May 20155:21 pmRNSHolding(s) in Company
1st May 201510:32 amRNSResult of General Meeting and Additional Listing
16th Apr 20155:48 pmRNSAdditional Listing
8th Apr 201511:33 amRNSFundraising update
2nd Apr 20152:34 pmRNSPreliminary results
2nd Apr 20152:34 pmRNSConditional fundraising of approximately £40m
23rd Mar 20157:00 amRNSClinical trial update
16th Feb 20157:00 amRNSPresentation at RNA Therapeutics conference
12th Feb 20157:00 amRNSSuccessful European patent appeal
27th Jan 20157:00 amRNSGrant of share options
5th Jan 20157:00 amRNSBoard Changes
15th Dec 20147:00 amRNSBoard appointment
1st Dec 20147:00 amRNSTrading update and capital markets presentation
1st Dec 20147:00 amRNSTechnology breakthrough
18th Nov 20147:00 amRNSPublication of study data
3rd Nov 201410:26 amRNSAdditional Listing
22nd Oct 20145:44 pmRNSNotification of Major Interest in Shares
23rd Sep 201411:41 amRNSAdditional Listing
16th Sep 20147:00 amRNSHalf year results
2nd Sep 20149:05 amRNSBoard change
27th Aug 20143:38 pmRNSNotice of Results
5th Aug 20147:00 amRNSPublication of pre-clinical study data
30th Jul 20147:00 amRNSLicensee confirms favourable trial outcome
18th Jul 20144:40 pmRNSSecond Price Monitoring Extn
18th Jul 20144:35 pmRNSPrice Monitoring Extension
17th Jul 20145:01 pmRNSNotification of major interest in shares
16th Jul 20147:00 amRNSCompletion of recruitment for phase 2a trial
9th Jul 20144:40 pmRNSSecond Price Monitoring Extn
9th Jul 20144:35 pmRNSPrice Monitoring Extension
3rd Jul 20144:35 pmRNSPrice Monitoring Extension
27th Jun 20144:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.